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Despite their low prevalence (annual global incidence of 5 cases out of 100,000 in the
European Union and United States), glioblastoma (GBM), malignant brain tumours,
result in high morbidity and mortality. Due to recurrences from infiltrating GBM cells
at the border of resection, the median survival is 14 months with the current standard
of care (surgical resection combined with adjuvant radiotherapy and/or
chemotherapy). The objective of this research project is to develop an implantable
hydrogel technology which will bridge the current therapeutic needs between surgical
resection and initiation of systemic regimens.
In this project, a polymer-free hydrogel prepared from biodegradable lipid
nanocapsules (LNCs) will act as a sustained-release matrix to deliver targeted
therapeutic nanoparticles specifically to cancer cells. This technology is expected to
limit GBM recurrences by i) maintaining therapeutic concentrations of anticancer
drugs at the resection border (without the necessity of crossing the blood-brain
barrier) and ii) targeting GBM cells specifically using a unique proprietary targeting
peptide (NFL-TBS.40-63) (NFL).Preliminary data shows that the peptide NFL can
adsorb at the surface of LNCs. This surface functionalization can be used to target
drug-loaded LNCs to GBM cells in vivo, and achieve therapeutic efficacy. In parallel,
when using a crosslinking agent, LNCs can self-associate in a network forming a
polymer-free hydrogel. When loaded with drugs, this hydrogel can provide sustained
release and improve in vivo therapeutic efficacy compared to the drug alone. The
GLIOGEL project will combine these two independent technologies to create unique
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